Date | Price Target | Rating | Analyst |
---|---|---|---|
11/22/2021 | $15.00 | Buy | BTIG |
4 - LENSAR, Inc. (0001320350) (Issuer)
4 - LENSAR, Inc. (0001320350) (Issuer)
4 - LENSAR, Inc. (0001320350) (Issuer)
LENSAR (NASDAQ:LNSR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.28) by 32.14 percent. This is a 52.5 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $10.588 million which beat the analyst consensus estimate of $10.550 million by 0.36 percent. This is a 28.31 percent increase over sales of $8.252 million the same period last year.
Lake Street initiates coverage on LENSAR (NASDAQ:LNSR) with a Buy rating and announces Price Target of $8.
LENSAR (NASDAQ:LNSR) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.22) by 59.09 percent. This is a 45.83 percent decrease over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $12.11 million which beat the analyst consensus estimate of $12.00 million by 0.88 percent. This is a 18.31 percent increase over sales of $10.23 million the same period last year.
LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 2,425 shares of the Company's common stock. The options were granted as of September 3, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $4.63 per share, which is equal to the closing price of the Company's common stock on the grant date. The options vest as to 25% of the total amount of the award on the
LENSAR®, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that management will participate in two upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment Conference On-demand presentation available Monday, September 9, 2024 at 7:00 a.m. Eastern Time. Lake Street Capital Markets 8th Annual Best Ideas Growth Conference Management will conduct one-on-one meetings with institutional investors on September 12, 2024 in New York. The on-demand H.C. Wainwright presentation will be available beginning at 7:00 a.m. Eastern Time on Monday, September 9, 2
17 New ALLY® Adaptive Cataract Treatment Systems placed in 2Q 2024; highest number of placements since launch Received Medical Device Regulation (MDR) certification (CE Mark) and Taiwan FDA approval granted for commercial distribution of ALLY; First EU and Southeast Asia systems shipped Continued robust worldwide procedure growth; 2Q 2024 procedure volumes increased 19% over 2Q 2023 Installed system base grew 16% over 2Q 2023 LENSAR®, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2024 and provided an update on key
BTIG initiated coverage of LENSAR with a rating of Buy and set a new price target of $15.00
SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00
SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00
4 - LENSAR, Inc. (0001320350) (Issuer)
4 - LENSAR, Inc. (0001320350) (Issuer)
4 - LENSAR, Inc. (0001320350) (Issuer)
10-Q - LENSAR, Inc. (0001320350) (Filer)
8-K - LENSAR, Inc. (0001320350) (Filer)
8-K - LENSAR, Inc. (0001320350) (Filer)
SC 13G/A - LENSAR, Inc. (0001320350) (Subject)
SC 13G/A - LENSAR, Inc. (0001320350) (Subject)
SC 13G/A - LENSAR, Inc. (0001320350) (Subject)
17 New ALLY® Adaptive Cataract Treatment Systems placed in 2Q 2024; highest number of placements since launch Received Medical Device Regulation (MDR) certification (CE Mark) and Taiwan FDA approval granted for commercial distribution of ALLY; First EU and Southeast Asia systems shipped Continued robust worldwide procedure growth; 2Q 2024 procedure volumes increased 19% over 2Q 2023 Installed system base grew 16% over 2Q 2023 LENSAR®, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2024 and provided an update on key
LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that the Company's second quarter 2024 financial results will be released before market open on Thursday, August 8, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, August 8, 2024 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (800) 274 8461 (Domestic) or (203) 518 9848 (International). The conference ID is LENSAR. To access the live webcast, please go to the Investors section of LENSAR's website at www.lensar.com
Total Revenue increased 28% and Procedure volume increased 25% over the first quarter of 2023 Increased ALLY® Adaptive Cataract Treatment System installed base to 65 systems LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2024 and provided an update on key operational initiatives. "Recognition of ALLY's advantages, its ability to achieve higher efficiencies for surgeons and staff as well as better surgical outcomes for patients, allowed us to deliver continued 20%+ revenue growth in the first quart